ARA-290

ARA-290 (cibinetide) is a 15-amino acid peptide developed by Araim Pharmaceuticals that functions as an agonist for the innate repair receptor (IRR), a cell surface receptor involved in damage sensing and cellular repair activation. The IRR is part of the innate immune system and responds to cellular stress, injury, and damage signals.

ARA-290 was discovered through structure-activity relationship studies of erythropoietin (EPO), the hormone responsible for red blood cell production. Researchers identified a minimal peptide domain of EPO responsible for activating repair mechanisms without the erythropoietic (blood cell-stimulating) effects. This led to development of ARA-290 as a selective innate repair pathway activator.

The peptide has shown promise in clinical development for neuropathic pain conditions, tissue healing, and recovery applications, with multiple Phase 2/Phase 3 trials underway or completed.

Innate repair receptor activation: ARA-290 binds to and activates the innate repair receptor, a sensor for cellular damage and stress on the surface of cells, particularly neurons and epithelial cells.

Cellular damage response: IRR activation triggers intracellular signaling cascades that activate repair mechanisms including: protein synthesis enhancement, mitochondrial function restoration, oxidative stress reduction, and apoptosis prevention in damaged cells.

Anti-inflammatory effects: ARA-290 reduces inflammatory cytokine production and immune cell infiltration, creating an environment conducive to healing rather than chronic inflammation.

Neuroprotection: The peptide shows particular efficacy in protecting and repairing nerve cells (neurons), reducing neuropathic pain and supporting neuronal recovery from injury or disease.

Tissue-specific repair: By activating innate repair pathways, ARA-290 promotes healing in multiple tissue types, with particular benefits for nerve tissue, skin, and other epithelial tissues.

Small Fiber Neuropathy (SFN): ARA-290 has shown efficacy in clinical trials for small fiber neuropathy, a condition involving damage to small nerve fibers causing neuropathic pain. Phase 2 trials demonstrated pain reduction and improved nerve fiber regeneration (Heij et al., 2012).

Diabetic Neuropathy: Trials in patients with diabetic peripheral neuropathy have shown improvements in pain scores and objective measures of nerve function with ARA-290 treatment.

Wound Healing: Preliminary data suggests ARA-290 may enhance wound healing through innate repair pathway activation, though more extensive clinical evaluation is ongoing.

Safety profile: Clinical trials have demonstrated favorable safety profiles with minimal adverse events. The peptide does not affect hemoglobin or red blood cell counts, unlike its EPO parent molecule.

Current development status: Araim Pharmaceuticals has advanced ARA-290 through multiple clinical trials for various indications. Recent focus includes neuropathic pain and rare disease indications with high unmet medical need.

• Neuropathic pain reduction — significant pain relief in nerve injury and disease
• Nerve regeneration support — enhanced small nerve fiber regeneration
• Wound and tissue healing — accelerated healing through innate repair activation
• Anti-inflammatory effects — reduced chronic inflammation supporting healing
• Neuroprotection — protection of nerve cells from damage and degeneration
• Cellular stress response — activation of cellular repair mechanisms
• No erythropoietic effects — unlike EPO, doesn't affect red blood cell production

Clinical trial dosing: ARA-290 is administered via subcutaneous injection, with typical research doses of 2-3 mg administered 1-2 times daily or every other day depending on the protocol.

Dosing schedules: Various protocols have been tested, including daily dosing, every-other-day dosing, and dose escalation periods. Common maintenance doses range from 2-3 mg per injection.

Duration: Clinical trials have typically run 4-12 weeks of active treatment, with some protocols including longer extension phases to assess sustained benefit.

Current availability: ARA-290 is an investigational peptide currently available only in registered clinical trials. It is not FDA-approved or commercially available outside trial settings.

Excellent safety profile: Clinical trials have demonstrated ARA-290 to have a very favorable safety profile with minimal serious adverse events.

Minimal side effects: Most commonly reported side effects are injection site reactions (redness, swelling, mild discomfort). Systemic side effects are rare and generally mild when they occur.

No hematologic effects: Unlike its EPO parent molecule, ARA-290 does not affect hemoglobin, hematocrit, or red blood cell counts, eliminating one class of potential safety concerns.

Immunogenicity: No significant immunogenic responses or antibody formation against ARA-290 have been reported in clinical trials, suggesting good long-term tolerability.

Theoretical considerations: As an innate repair pathway activator, potential theoretical concerns exist regarding effects on cell proliferation or differentiation in certain tissues, though no clinical evidence supports adverse effects.